Investigating new treatments for prostate cancer by blocking androgen receptors
Structural and functional analysis of a novel class of androgen receptor antagonists
This study is looking at a new treatment option for men with metastatic prostate cancer who haven't had success with current therapies, by testing a new drug that aims to block certain receptors in the body to help improve their response to treatment.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10831072 on NIH RePORTER |
What this research studies
This research focuses on developing a new class of androgen receptor antagonists to improve treatment for metastatic prostate cancer. Current therapies often lead to resistance, resulting in castration-resistant prostate cancer, which is a significant challenge in treatment. The researchers are exploring a small molecule, SID 3712502, and its structural analogues to find effective ways to inhibit androgen receptors without competing with hormones. This approach aims to provide a more durable response in patients who have not benefited from existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic prostate cancer who have experienced relapse after standard androgen deprivation therapy.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone androgen deprivation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for prostate cancer, potentially extending survival and improving quality of life for patients.
How similar studies have performed: While there have been advancements in androgen receptor-targeting therapies, this specific approach using novel antagonists is relatively new and has not been extensively tested.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Wang, Zhou — University of Pittsburgh at Pittsburgh
- Study coordinator: Wang, Zhou
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.